In May, Merck’s Phase 3 KEYNOTE-B96 trial (also known as ENGOT-ov65), met its primary endpoint of progression-free survival (PFS) for platinum-resistant recurrent ovarian cancer whose tumors ...

ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost ...

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with ...

Keytruda (pembrolizumab) contributed almost $2.3 billion out of Merck’s total sales of $10.8 billion in the quarter, a 55% rise that was driven by use in first-line non-small cell lung cancer ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide ( ) with these numbers expected to grow. The American Cancer Society ...

Merck (NYSE: MRK) last month announced that its bestselling therapy, Keytruda, as part of a combination regimen, reached the primary endpoint in a Phase 3 trial for a certain type of ovarian cancer.

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people ...

The Zacks Consensus Estimate for J&J’s 2025 sales and EPS implies a year-over-year increase of 2.7% and 6.2%, respectively.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.